A Randomized, Double-blind, Placebo-controlled, Single and Multiple Ascending Dose, Phase 1 Clinical Trial to Evaluate Pharmacokinetics, Pharmacodynamics, Safety and Tolerability After Oral Administration of AJH-2947 in Healthy Korean or Caucasian Male Subjects
Latest Information Update: 21 Oct 2024
At a glance
- Drugs JM 2947 (Primary)
- Indications Diabetic neuropathies; Neuropathic pain; Postherpetic neuralgia
- Focus Adverse reactions; Pharmacokinetics
- Sponsors JMackem
Most Recent Events
- 15 Oct 2024 Planned End Date changed from 1 Apr 2025 to 1 Sep 2025.
- 15 Oct 2024 Planned primary completion date changed from 1 Feb 2025 to 1 Apr 2025.
- 07 Dec 2023 New trial record